VRTX
$454.00-4.05 (-0.88%)
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF).
Recent News
7 Companies That Look Primed to Beat on Earnings
We looked for promising names in materials and healthcare, and found some investments that should thrive in today’s economy.
Vertex Stock Falls 4.8% in a Month: Buying Opportunity or Red Flag?
VRTX stock slips nearly 5% as concerns over new drug uptake and pipeline setbacks weigh, even as its dominant CF franchise continues to drive steady growth.
My Top 3 Drug Stocks for March 2026
These companies have impressive track records of navigating the biggest challenges in their industry.
Assessing Vertex Pharmaceuticals (VRTX) Valuation After Positive RAINIER Trial Update And Accelerated IgAN Filing
Why the RAINIER trial update matters for Vertex Pharmaceuticals (VRTX) Vertex Pharmaceuticals (VRTX) has drawn fresh attention after reporting positive interim Phase 3 RAINIER results for povetacicept in IgA nephropathy, including clinically meaningful proteinuria reductions and a safety profile that supported continued development. Alongside the data, the company is moving quickly with a rolling Biologics License Application and using a priority review voucher. These steps point to a...
Best Growth Stock to Buy Right Now: Eli Lilly vs. Vertex Pharmaceuticals
Both have plenty to offer investors, but one has a better outlook.